Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation

English version

Autoři: Fabienne Witassek ^aff001; Anne Springer ^aff002; Luise Adam ^aff004; Stefanie Aeschbacher ^aff002; Jürg H. Beer ^aff005; Steffen Blum ^aff002; Leo H. Bonati ^aff006; David Conen ^aff002; Richard Kobza ^aff008; Michael Kühne ^aff002; Giorgio Moschovitis ^aff009; Stefan Osswald ^aff002; Nicolas Rodondi ^aff004; Christian Sticherling ^aff002; Thomas Szucs ^aff011; Matthias Schwenkglenks ^aff001;
Působiště autorů: Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland ^aff001; Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland ^aff002; Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland ^aff003; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland ^aff004; Department of Medicine, Cantonal Hospital of Baden, Baden, and Molecular Cardiology, University Hospital of Zurich, Zurich, Switzerland ^aff005; Neurology Division and Stroke Centre, Department of Clinical Research, University Hospital Basel, Basel, Switzerland ^aff006; Population Health Research Institute, McMaster University, Hamilton, Canada ^aff007; Department of Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland ^aff008; Division of Cardiology, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano, Ticino, Lugano, Switzerland ^aff009; Institute of Primary Health Care (BIHAM), University of Bern, Berne, Switzerland ^aff010; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland ^aff011
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0226730

Souhrn

Aims

This study aimed to analyse health related quality of life (HRQoL) for patients with different atrial fibrillation (AF) types and to identify patient characteristics, symptoms and comorbidities that influence HRQoL.

Methods

We used baseline data from the Swiss Atrial Fibrillation (Swiss-AF) study, a prospective multicentre observational cohort study conducted in 13 clinical centres in Switzerland. Between April 2014 and August 2017, 2415 AF patients were recruited. Patients were included in this analysis if they had baseline HRQoL data as assessed with EQ-5D-based utilities and visual analogue scale (VAS) scores. Patient characteristics and HRQoL were described stratified by AF type. The impact of symptoms, comorbidities and socio-economic factors on HRQoL was analysed using multivariable regression analysis.

Results

Based on 2412 patients with available baseline HRQoL data, the lowest unadjusted mean HRQoL was found in patients with permanent AF regardless of whether measured with utilities (paroxysmal: 0.83, persistent: 0.84, permanent: 0.80, p<0.001) or VAS score (paroxysmal: 73.6, persistent: 72.8, permanent: 69.2, p<0.001). In multivariable analysis of utilities and VAS scores, higher European Heart Rhythm Association (EHRA) score, recurrent falls and several comorbidities showed a strong negative impact on HRQoL while AF type was no longer associated with HRQoL.

Conclusions

Multiple factors turned out to influence HRQoL in AF patients. After controlling for several comorbidities, the EHRA score was one of the strongest predictors independent of AF type. The results may be valuable for better patient assessment and provide a reference point for further QoL and health economic analyses in AF populations.

Klíčová slova:

Patients – Arteries – Heart failure – Deep vein thrombosis – Atrial fibrillation – Fatigue – Sleep apnea

Zdroje

1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–20. doi: 10.2147/CLEP.S47385 24966695; PubMed Central PMCID: PMC4064952.

2. Blum S, Muff C, Aeschbacher S, Ammann P, Erne P, Moschovitis G, et al. Prospective Assessment of Sex-Related Differences in Symptom Status and Health Perception Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2017;6(7). doi: 10.1161/JAHA.116.005401 28666988; PubMed Central PMCID: PMC5586278.

3. Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305(20):2080–7. doi: 10.1001/jama.2011.659 21610240; PubMed Central PMCID: PMC3105776.

4. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448 e1–19. doi: 10.1016/j.amjmed.2005.10.057 16651058.

5. Lane DA, Lip GY. Quality of life in older people with atrial fibrillation. J Interv Card Electrophysiol. 2009;25(1):37–42. doi: 10.1007/s10840-008-9318-y 19034639.

6. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36(4):1303–9. doi: 10.1016/s0735-1097(00)00886-x 11028487.

7. Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006;152(6):1097–103. doi: 10.1016/j.ahj.2006.08.011 17161061; PubMed Central PMCID: PMC1820843.

8. Roalfe AK, Bryant TL, Davies MH, Hackett TG, Saba S, Fletcher K, et al. A cross-sectional study of quality of life in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation Treatment of the Aged study. Europace. 2012;14(10):1420–7. doi: 10.1093/europace/eus102 22581625.

9. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res. 2010;19(3):381–90. doi: 10.1007/s11136-010-9591-y 20108048.

10. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. doi: 10.1093/eurheartj/ehw210 27567408.

11. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O'Neill J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632–9. doi: 10.1161/CIRCEP.112.970749 22787011.

12. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422–34. doi: 10.1093/eurheartj/ehi505 16204266.

13. Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type of atrial fibrillation. Rev Esp Cardiol. 2010;63(12):1402–9. doi: 10.1016/s1885-5857(10)70274-7 21144400.

14. Conen D, Rodondi N, Mueller A, Beer J, Auricchio A, Ammann P, et al. Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Med Wkly. 2017;147:w14467. doi: 10.4414/smw.2017.14467 28695548.

15. Conen D, Rodondi N, Muller A, Beer JH, Ammann P, Moschovitis G, et al. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019;73(9):989–99. doi: 10.1016/j.jacc.2018.12.039 30846109.

16. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72. doi: 10.1016/0168-8510(96)00822-6 10158943.

17. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43. doi: 10.3109/07853890109002087 11491192.

18. Matter-Walstra K, Klingbiel D, Szucs T, Pestalozzi BC, Schwenkglenks M. Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? Pharmacoeconomics. 2014;32(6):591–9. doi: 10.1007/s40273-014-0151-0 24671924.

19. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007;28(22):2803–17. doi: 10.1093/eurheartj/ehm358 17897924.

20. Sen S, Bradshaw L. Comparison of Relative Fit Indices for Diagnostic Model Selection. Appl Psychol Meas. 2017;41(6):422–38. doi: 10.1177/0146621617695521 29881100; PubMed Central PMCID: PMC5978522.

21. Austin PC, Escobar M, Kopec JA. The use of the Tobit model for analyzing measures of health status. Qual Life Res. 2000;9(8):901–10. doi: 10.1023/a:1008938326604 11284209.

22. McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. JAMA. 2014;312(13):1342–3. doi: 10.1001/jama.2014.13128 25268441.

23. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92. doi: 10.1097/01.MLR.0000062554.74615.4C 12719681.

24. Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, et al. Patient factors associated with quality of life in atrial fibrillation. Am Heart J. 2016;182:135–43. doi: 10.1016/j.ahj.2016.08.003 27914493; PubMed Central PMCID: PMC5584577.

25. Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, et al. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015;8(4):393–402. doi: 10.1161/CIRCOUTCOMES.114.001303 26058720.

26. Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018;131(3):269–75 e2. doi: 10.1016/j.amjmed.2017.10.036 29122636.

27. Fumagalli S, Potpara TS, Bjerregaard Larsen T, Haugaa KH, Dobreanu D, Proclemer A, et al. Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. Europace. 2017;19(11):1896–902. doi: 10.1093/europace/eux288 29040554.

28. Alegret JM, Vinolas X, Arias MA, Martinez-Rubio A, Rebollo P, Rafols C, et al. New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci. 2014;11(7):680–4. doi: 10.7150/ijms.8916 24843316; PubMed Central PMCID: PMC4025166.

29. Keita I, Aubin-Auger I, Lalanne C, Aubert JP, Chassany O, Duracinsky M, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017;11:1625–34. doi: 10.2147/PPA.S131157 29026288; PubMed Central PMCID: PMC5626412.

30. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965–72. doi: 10.1093/europace/eut395 24534264; PubMed Central PMCID: PMC4070972.

31. Andrade JG, Deyell MW, Lee AYK, Macle L. Sex Differences in Atrial Fibrillation. Can J Cardiol. 2017. doi: 10.1016/j.cjca.2017.11.022 29455950.

32. Payakachat N, Ali MM, Tilford JM. Can The EQ-5D Detect Meaningful Change? A Systematic Review. Pharmacoeconomics. 2015;33(11):1137–54. doi: 10.1007/s40273-015-0295-6 26040242; PubMed Central PMCID: PMC4609224.